JP2010521442A5 - - Google Patents

Download PDF

Info

Publication number
JP2010521442A5
JP2010521442A5 JP2009553196A JP2009553196A JP2010521442A5 JP 2010521442 A5 JP2010521442 A5 JP 2010521442A5 JP 2009553196 A JP2009553196 A JP 2009553196A JP 2009553196 A JP2009553196 A JP 2009553196A JP 2010521442 A5 JP2010521442 A5 JP 2010521442A5
Authority
JP
Japan
Prior art keywords
composition according
composition
nsaid
glycol ether
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009553196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521442A (ja
Filing date
Publication date
Priority claimed from GBGB0704846.5A external-priority patent/GB0704846D0/en
Application filed filed Critical
Publication of JP2010521442A publication Critical patent/JP2010521442A/ja
Publication of JP2010521442A5 publication Critical patent/JP2010521442A5/ja
Pending legal-status Critical Current

Links

JP2009553196A 2007-03-13 2008-02-15 局所製剤処方 Pending JP2010521442A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0704846.5A GB0704846D0 (en) 2007-03-13 2007-03-13 Topical pharmaceutical formulation
PCT/GB2008/000540 WO2008110741A2 (en) 2007-03-13 2008-02-15 Topical pharmaceutical formulation

Publications (2)

Publication Number Publication Date
JP2010521442A JP2010521442A (ja) 2010-06-24
JP2010521442A5 true JP2010521442A5 (enExample) 2011-04-14

Family

ID=37988913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009553196A Pending JP2010521442A (ja) 2007-03-13 2008-02-15 局所製剤処方

Country Status (21)

Country Link
US (1) US8541470B2 (enExample)
EP (2) EP2131813B1 (enExample)
JP (1) JP2010521442A (enExample)
CN (1) CN101663022A (enExample)
AU (1) AU2008224735B2 (enExample)
BR (1) BRPI0808887A2 (enExample)
CA (1) CA2680074C (enExample)
CO (1) CO6220926A2 (enExample)
DK (1) DK2131813T3 (enExample)
ES (1) ES2391914T3 (enExample)
GB (1) GB0704846D0 (enExample)
MX (1) MX2009009758A (enExample)
MY (1) MY149545A (enExample)
NZ (1) NZ579895A (enExample)
PL (1) PL2131813T3 (enExample)
PT (1) PT2131813E (enExample)
RU (1) RU2468794C2 (enExample)
SG (1) SG179480A1 (enExample)
TW (1) TWI367110B (enExample)
UA (1) UA100509C2 (enExample)
WO (1) WO2008110741A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416743A (pt) * 2003-11-20 2007-01-16 Novo Nordisk As formulação farmacêutica, e, métodos de preparar uma formulação de peptìdeo apropriada para uso em um dispositivo de injeção, para reduzir depósitos em equipamento de produção e no produto final, e para reduzir o entupimento de dispositivos de injeção por uma formulação de peptìdeo
SG10201703082XA (en) 2008-10-17 2017-06-29 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AU2010306768B2 (en) 2009-10-14 2016-08-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
AU2013246485A1 (en) 2012-04-12 2014-10-16 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
SG11201505245XA (en) * 2013-01-14 2015-08-28 Infirst Healthcare Ltd Compositions and methods for treating severe pain
EP3578172B1 (en) * 2013-01-14 2021-03-24 InFirst Healthcare Limited Solid solution compositions and use in chronic inflammation
HK1218621A1 (zh) * 2013-02-04 2017-03-03 Infirst Healthcare Limited 用於治疗慢性炎症和炎性疾病的组合物及方法
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
GB201502845D0 (en) * 2015-02-20 2015-04-08 Futura Medical Dev Ltd Topical pharmaceutical formulation
FR3041534B1 (fr) 2015-09-30 2019-03-15 Vetoquinol Sa Composition de nettoyant auriculaire
GB201609968D0 (en) * 2016-06-07 2016-07-20 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
CA3055159A1 (en) * 2017-03-07 2018-09-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Topical delivery systems for active compounds
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CN111050750B (zh) 2017-08-24 2024-09-24 诺和诺德股份有限公司 Glp-1组合物及其用途
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー/エス 医薬製剤
GB2596286B (en) 2020-06-20 2023-01-25 Francis Davis Adrian Adherence to topical therapy
GB2597526A (en) 2020-07-27 2022-02-02 Incanthera R&D Ltd Topical formulation
AU2021318827A1 (en) 2020-07-27 2023-03-16 Incanthera (R&D) Ltd Topical formulation
GB202012836D0 (en) 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06104624B2 (ja) * 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
PE20011092A1 (es) * 2000-02-14 2001-11-12 Procter & Gamble Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
PE20040321A1 (es) 2002-08-22 2004-07-15 Novartis Consumer Health Sa Composicion topica que comprende diclofenaco
US7132452B2 (en) * 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
WO2005027977A2 (en) 2003-09-22 2005-03-31 Agis Industries (1983) Ltd. Diclofenac compositions for the treatment of skin disorders
EP1588697A1 (en) 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
US20050244522A1 (en) 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents

Similar Documents

Publication Publication Date Title
JP2010521442A5 (enExample)
RU2009136228A (ru) Фармацевтическая композиция для топического применения
JP5734479B2 (ja) ジクロフェナクの新規な非水性外用溶液およびそれを調製するためのプロセス
JP2015527386A5 (enExample)
JP2010513500A5 (enExample)
RU2012137785A (ru) Лечение респираторных заболеваний
JP2008540394A5 (enExample)
SG177736A1 (en) Dermal formulations of dp2 receptor antagonists
JP2016508158A5 (enExample)
JP2014185132A5 (enExample)
JP2012530719A5 (enExample)
RS53887B1 (sr) Jedinjenje sa topikalnom primenom za aktinične keratoze
JP2014509655A5 (enExample)
JP2013515020A5 (enExample)
CN108025078A (zh) 用于nsaid的固体溶液组合物
TW201444553A (zh) 外用醫藥組成物
JP2008531693A5 (enExample)
CN102770121A (zh) 包含溶剂混合物和维生素d衍生物或类似物的药物组合物
JP2018505905A (ja) 局所医薬製剤
JP2014510156A5 (enExample)
JP5642658B2 (ja) 非水性貼付剤
JP2014114249A (ja) 基剤、及び皮膚外用剤
JP2008522972A5 (enExample)
JP6253495B2 (ja) ロキソプロフェンを含有する外用剤組成物
WO2015016698A1 (es) Composición farmacéutica con agentes antiinflamatorios y proceso de producción